Andre Fedier
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Ex vivo drug sensitivity testing predicts treatment outcomes in advanced ovarian cancer.
Journal: NPJ precision oncology
Published: June 12, 2025
Protocol for quantifying drug sensitivity in 3D patient-derived ovarian cancer models.
Journal: STAR protocols
Published: February 08, 2024
MyCTC chip: microfluidic-based drug screen with patient-derived tumour cells from liquid biopsies.
Journal: Microsystems & nanoengineering
Published: July 28, 2022
Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer.
Journal: Cell death & disease
Published: April 26, 2022
Glycosphingolipids are mediators of cancer plasticity through independent signaling pathways.
Journal: Cell reports
Published: February 04, 2022
Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines.
Journal: International journal of oncology
Published: September 20, 2021
Collagen-rich omentum is a premetastatic niche for integrin α2-mediated peritoneal metastasis.
Journal: eLife
Published: May 28, 2020
Outcome in serous ovarian cancer is not associated with LATS expression.
Journal: Journal of cancer research and clinical oncology
Published: September 03, 2019
Diaphragmatic smears are not of additional benefit in the detection of peritoneal spread in gynecological cancers.
Journal: Experimental and therapeutic medicine
Published: October 10, 2017
ABO blood groups as a prognostic factor for recurrence in ovarian and vulvar cancer.
Journal: PloS one
Published: January 26, 2017
MELK expression in ovarian cancer correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of ovarian cancer cells.
Journal: Gynecologic oncology
Published: November 12, 2016
Last Updated: 09/26/2026